Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
You may also be interested in...
Combination Strategies A Common Thread In NASH R&D
Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.